None yet ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 2 |
| 222 | Primary nephrotic syndrome | 2 |
51. Scleroderma
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-005116-21-PL (EUCTR) | 27/09/2021 | 25/06/2021 | FT011 for Scleroderma | A phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, oforal FT011 in participants with diffuse systemic sclerosis - FT011 for scleroderma | diffuse systemic sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10012977;Term: Diffuse systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: FT011 100 mg Product Code: FT011 INN or Proposed INN: None yet Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid Product Name: FT011 200 mg Product Code: FT011 INN or Proposed INN: None yet Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | Certa Therapeutics Pty Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Spain;Poland;Ukraine;Australia;Russian Federation;Netherlands | ||
| 2 | EUCTR2020-005116-21-ES (EUCTR) | 22/07/2021 | 22/07/2021 | FT011 for Scleroderma | A phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, oforal FT011 in participants with diffuse systemic sclerosis - FT011 for scleroderma | diffuse systemic sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10012977;Term: Diffuse systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: FT011 100 mg Product Code: FT011 INN or Proposed INN: None yet Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid Product Name: FT011 200 mg Product Code: FT011 INN or Proposed INN: None yet Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | Certa Therapeutics Pty Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Poland;Spain;Ukraine;Australia;Russian Federation;Netherlands |
222. Primary nephrotic syndrome
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000384-23-DE (EUCTR) | 19/12/2022 | 17/05/2022 | A study to test BI 764198 in people with a type of kidney disease calledfocal segmental glomerulosclerosis. | A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis - PoCP study in FSGS | Focal segmental glomerulosclerosis MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21] | Product Code: BI 764198 INN or Proposed INN: None yet Other descriptive name: BI 764198 Product Code: BI 764198 INN or Proposed INN: None yet Other descriptive name: BI 764198 Product Code: BI 764198 INN or Proposed INN: None yet Other descriptive name: BI 764198 | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | France;United States;Hungary;Belgium;Spain;Ireland;Australia;Germany;United Kingdom;Italy;China | ||
| 2 | EUCTR2020-000384-23-ES (EUCTR) | 17/05/2022 | 28/03/2022 | A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). | A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis - PoCP study in FSGS | Glomerulosclerosis MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21] | Product Code: BI 764198 INN or Proposed INN: None yet Other descriptive name: BI 764198 Product Code: BI 764198 INN or Proposed INN: None yet Other descriptive name: BI 764198 Product Code: BI 764198 INN or Proposed INN: None yet Other descriptive name: BI 764198 | Boehringer Ingelheim España S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | United States;Hungary;Belgium;France;Spain;Ireland;Australia;Germany;United Kingdom;Italy |